Pharmaceutical Technology

NOVEMBER 17, 2022

This marks the first update to NICE’s endometriosis guidelines since 2017, representing a huge milestone for patients and practitioners alike. This delay in diagnosis ultimately leads to disease progression and associated complications, such as chronic pelvic pain and infertility, which greatly affects the patients’ quality of life.

Management 102

Management Pharmacology Side effects Patients 102

European Pharmaceutical Review

JANUARY 11, 2024

The current medications (opioid and non-opioid) often force the patients to make an unfortunate choice between efficacy and debilitating side effects, leading to a cycling through multiple different therapies and suboptimal treatment response. 2017; 6(S1):1–3. Neuropathic pain: The scope of the problem. Pain and Therapy. Internet] NIH.

Medicine 102

Medicine Pharmacology Management Side effects 102

pharmaphorum

OCTOBER 25, 2022

The eyedrop formulation of UNR844 (lipoic acid/choline ester chloride) was acquired as part of the group’s buyout of privately-held ophthalmology biotech Encore Vision for $375 million upfront in 2017, and was designed to work by restoring the elasticity of the eye’s lens that declines with age.

Pharmacology 119

Pharmacology Pharma Sales FDA 119

Pharmaceutical Technology

FEBRUARY 8, 2023

On February 7, at a town hall organised to discuss clinical trial designs for gene therapies, FDA experts pushed pharma players to look for ways to establish clinical effectiveness despite the challenges in recruiting patients with rare diseases.

FDA 105

FDA Patients Pharmacology Pharmaceutical 105

Clarivate

FEBRUARY 28, 2023

LHON mutation rate variability affects therapeutic efficacy Most LHON patients carry one of three pathogenic mitochondrial DNA mutations (11778G>A [ND4], 14484T>C [ND6] and 3460G>A [ND1]) known as primary LHON mutations. We identified patients with an LHON diagnosis using ICD-10 and ICD-9 codes H47.2 The Clarivate U.S.

Patients 98

Patients Prescription Pharmacology Healthcare 98

European Pharmaceutical Review

DECEMBER 11, 2023

The first approved ASO was designed for injection directly into the eye for the local treatment of cytomegalovirus (CMV) retinitis in immunocompromised AIDS patients. Known linkers in the RNA field are used to bond together the two pharmacologically active molecular entities and can be applied to multiple oligonucleotide modalities.

Safety 98

Safety Pharmacology Engineering Medical 98

Legacy MEDSearch

AUGUST 25, 2022

The PiCSO-AMI-II multicenter, randomized trial will enroll 300 patients with anterior ST-segment Elevation Myocardial Infarction (STEMI) presenting with TIMI flow 0, 1, and 2 within 12 hours of symptom onset. PiCSO therapy is a promising new therapy to reduce infarct size and improve outcomes in anterior STEMI patients. said Prof. “In

Medical 52

Medical FDA Recruitment Pharmacology 52